1. Home
  2. SLGL vs IHT Comparison

SLGL vs IHT Comparison

Compare SLGL & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLGL
  • IHT
  • Stock Information
  • Founded
  • SLGL 1997
  • IHT 1971
  • Country
  • SLGL Israel
  • IHT United States
  • Employees
  • SLGL N/A
  • IHT N/A
  • Industry
  • SLGL Biotechnology: Pharmaceutical Preparations
  • IHT Investment Bankers/Brokers/Service
  • Sector
  • SLGL Health Care
  • IHT Finance
  • Exchange
  • SLGL Nasdaq
  • IHT Nasdaq
  • Market Cap
  • SLGL 19.3M
  • IHT 19.0M
  • IPO Year
  • SLGL 2018
  • IHT N/A
  • Fundamental
  • Price
  • SLGL $13.00
  • IHT $1.94
  • Analyst Decision
  • SLGL Buy
  • IHT
  • Analyst Count
  • SLGL 1
  • IHT 0
  • Target Price
  • SLGL $40.00
  • IHT N/A
  • AVG Volume (30 Days)
  • SLGL 13.9K
  • IHT 6.5K
  • Earning Date
  • SLGL 08-15-2025
  • IHT 09-15-2025
  • Dividend Yield
  • SLGL N/A
  • IHT 1.08%
  • EPS Growth
  • SLGL N/A
  • IHT N/A
  • EPS
  • SLGL N/A
  • IHT N/A
  • Revenue
  • SLGL $12,103,000.00
  • IHT $7,505,309.00
  • Revenue This Year
  • SLGL N/A
  • IHT N/A
  • Revenue Next Year
  • SLGL $31.17
  • IHT N/A
  • P/E Ratio
  • SLGL N/A
  • IHT N/A
  • Revenue Growth
  • SLGL 603.66
  • IHT N/A
  • 52 Week Low
  • SLGL $3.34
  • IHT $1.51
  • 52 Week High
  • SLGL $16.50
  • IHT $2.70
  • Technical
  • Relative Strength Index (RSI)
  • SLGL 87.12
  • IHT 38.27
  • Support Level
  • SLGL $10.95
  • IHT $1.70
  • Resistance Level
  • SLGL $12.90
  • IHT $2.28
  • Average True Range (ATR)
  • SLGL 1.12
  • IHT 0.14
  • MACD
  • SLGL 0.40
  • IHT -0.02
  • Stochastic Oscillator
  • SLGL 95.73
  • IHT 40.68

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About IHT InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.

Share on Social Networks: